Compounded GLP-1 vs labeled: what the FDA says

Key takeaways

• Branded GLP-1 products (Wegovy, Ozempic, Zepbound, Mounjaro) clear full FDA chemistry-and-manufacturing review; compounded versions do not go through the same approval, safety, or labeling process .
• Compounding leaned on the FDA shortage list for its legal basis. Tirzepatide came off the shortage list in October 2024 and semaglutide in February 2025, which narrowed that basis sharply .
• The FDA states semaglutide salt forms (sodium, acetate) are not the same active ingredient as the approved semaglutide base and are not established as safe and effective .
• The FDA has documented dosing errors with compounded GLP-1s, including 5-fold and 10-fold overdoses, hospitalizations, and at least one death .
• Compounded product does not inherit the STEP or SURMOUNT efficacy evidence; the molecule may transfer, but formulation, salt form, stability, and identity verification do not come with it .

Skip to:

• Should you trust a compounded vial: the tiers
• The regulatory distinction in plain language
• 503A vs 503B: who can compound what
• The shortage history that opened and closed the lane
• The salt-form problem
• The dosing errors are documented, and one was fatal
• What the trial data does and does not transfer
• Telehealth and international research-chemical channels
• Final read

Should you trust a compounded vial: the tiers

Here is the practical ranking by regulatory tier, the source, the verdict, and the load-bearing fact behind each. The drop from tier to tier is mostly about how much identity and manufacturing oversight stands between you and the vial.

• Labeled FDA-approved product (Wegovy, Ozempic, Zepbound, Mounjaro): highest tier. Full chemistry-and-manufacturing review, post-market safety surveillance, and the actual STEP and SURMOUNT trial evidence .
• 503A or 503B pharmacy compounding from semaglutide or tirzepatide base: middle tier. Legitimate clinical pathway, but no FDA approval, and the legal basis narrowed when both drugs left the shortage list .
• Salt-form compounded product (semaglutide sodium or acetate): flagged tier. The FDA says these are not the same active ingredient as the approved base and are not established as safe and effective .
• International or research-chemical vials labeled not for human use: bottom tier. No oversight, frequently no identity verification, dosing-error and contamination risk stacked on top of the regulatory risk .

The regulatory distinction in plain language

Branded GLP-1 products are FDA-approved finished drugs with full chemistry, manufacturing, and controls review, post-market safety surveillance, and labeled indications . Compounded GLP-1 preparations are made by 503A pharmacies for individual prescriptions or by 503B outsourcing facilities for bulk distribution, and they do not go through that approval and labeling apparatus.

The compounding pathway exists for real reasons (drug shortage, individualized dosing, allergen avoidance), but it is not a generic-equivalent pathway. There is no generic semaglutide approved under the usual abbreviated pathway, because semaglutide is still under patent and Novo Nordisk has not licensed one. So a cheaper compounded vial is not a generic in the sense people assume; it is a different regulatory animal.

503A vs 503B: who can compound what

• 503A pharmacies: state-licensed compounding pharmacies. Compound for individual patient prescriptions only. Cannot compound copies of commercially available drugs, except from a drug that was on the FDA shortage list at the time of compounding or from substances on the 503A bulks list.
• 503B outsourcing facilities: register with the FDA, follow modified manufacturing standards, and may compound without a patient-specific prescription for office use or bulk distribution. Subject to FDA inspection.
• Shortage discretion: while a drug is on the shortage list, FDA enforcement discretion typically allows both 503A and 503B compounding of it. Once it leaves the list, the legal basis for routine compounding narrows substantially.

The shortage history that opened and closed the lane

Semaglutide injectables entered FDA shortage status in March 2022 and stayed on intermittently through 2024; tirzepatide entered in December 2022. The shortages drove a large expansion of compounded supply through both 503A and 503B channels, since the shortage listing was the legal hook. The FDA shortage database is the authoritative current reference .

The FDA removed tirzepatide from the shortage list in October 2024 (upheld after litigation) and semaglutide in February 2025. Those removals triggered notices that 503B facilities and 503A pharmacies could no longer routinely compound copies of the branded drugs. This shortage-to-resolution turn is the single most important regulatory shift in this space, and it is why what was permissible in 2024 may not be in 2026 .

The salt-form problem

Some compounded products used semaglutide sodium or semaglutide acetate instead of the semaglutide base in the approved product. The FDA has stated plainly that these salt forms are not the same active ingredient as semaglutide base, that there is no evidence they are safe and effective, and that compounding from them does not fall within the shortage-related allowances .

The practical fallout: a vial labeled semaglutide from a compounded source may contain a salt form with a different molecular weight, different stability, and uncharacterized clinical equivalence. The milligram-to-milligram conversion people carry over from the branded pen is not strictly correct for a salt-form preparation, which is one more way the dose math goes wrong.

The dosing errors are documented, and one was fatal

The FDA has issued explicit alerts on dosing errors with compounded GLP-1 products, especially when patients self-draw from multi-dose vials with insulin syringes, the units-versus-milligrams distinction is unclear, or the concentration differs from the branded reference. The reports include 5-fold and 10-fold overdoses, hospitalizations, and at least one death .

• Concentration mismatch: a compounded vial may not match the branded product's mg per mL.
• Units confusion: insulin-syringe U-100 markings are insulin units (0.01 mL each), not milligrams; a user converting from a brand pen can misread by an order of magnitude.
• Reconstitution variability: powder formulations need the correct diluent volume, and small errors compound across repeated draws.
• Salt-form math: a branded mg conversion does not necessarily equal the mg of active base in a salt-form preparation.
• Stale vial: peptide stability in a multi-dose reconstituted vial is not the same as a sealed pen cartridge, and concentration drifts over weeks.

What the trial data does and does not transfer

The efficacy claims for branded GLP-1s come from STEP and SURMOUNT . Compounded versions were not in those trials. Pharmacology that depends on the molecule itself (receptor binding, the half-life built into the structure) plausibly carries over when the molecule is genuinely the same. Pharmacology that depends on formulation (excipients, stability, fill volume) does not necessarily carry over, and the FDA's manufacturing review is the only routine check on those factors for the labeled product.

Telehealth and international research-chemical channels

A large share of compounded GLP-1 dispensing moved through telehealth platforms that pair an asynchronous prescriber consult with a 503A pharmacy fulfillment, usually advertising prices well below the branded cash price. The clinical model differs from in-person prescribing in monitoring, follow-up, and contraindication screening, and FDA attention to it rose through 2025 with warning letters over promotional claims and salt-form dispensing .

A separate channel sells research-only or not-for-human-use semaglutide and tirzepatide vials internationally, outside FDA jurisdiction and any compounding license. These carry zero manufacturing oversight and frequently zero identity verification, so the dosing-error and contamination risks stack on top of the regulatory ones. The research-only disclaimer is not a regulatory category and does not protect the buyer; the FDA has issued repeated warnings about counterfeit and unapproved GLP-1 products entering through international shipping .

Final read

The compounded GLP-1 ecosystem grew during the 2022 to 2024 shortage and is contracting now that the shortages are resolved and enforcement has tightened. The labeled products have the full manufacturing review and the actual trial evidence. Pharmacy-compounded base (not salt forms) is the next tier and is on narrower legal ground than it was. International research-chemical vials are the lowest tier and carry the most risk, including the documented dosing-error deaths .

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article. Whether to use compounded or labeled GLP-1 is a clinical and pharmacy decision that belongs with a prescriber and a licensed pharmacy, not an online vendor.

For how this article was sourced and reviewed, see Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 7 entries, all primary canon (FDA, PubMed, DailyMed), last reviewed 2026-05-28.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.